Releases Geral
BioPharmaSpec Announces Major Investments in Mass Spectrometry and Related Instrumentation
AGÊNCIA DE COMUNICAÇÃO Conteúdo de responsabilidade da empresa 3 de junho de 2024
BioPharmaSpec
MALVERN, Pa. and ST. SAVIOUR, Jersey, June 03, 2024 (GLOBE NEWSWIRE) — BioPharmaSpec (BioPharmaSpec), the leading global Contract Research Organization (CRO) for discovery and preclinical characterization of biopharmaceuticals, has made major new investments in instrumentation, including top-of-the-range Mass Spectrometers, to support its clients in their product development goals.
On June 1st, 2024, BioPharmaSpec announced that it had recently purchased a range of new Mass Spectrometry instrumentation, including: Waters Select Series CYCLIC Ion Mobility Separation (IMS) High Definition LC-MS/MS with ECD, SCIEX ZenoTOF 7600 LC-MS/MS with EAD, Waters Xevo TQ Absolute and Waters Xevo G3 LC-MS/MS Q-TOFs.
To further support Clients with the provision of their first-class characterization services, BioPharmaSpec has also expanded its overall analytical instrumentation portfolio with the Bio-Techne (Protein Simple) Maurice Flex icIEF, CE-SDS and cIEF instrument, two Shimadzu PPSQ-53A Gas Phase Sequencers and a Wyatt DAWN Ambient 18 angle Multi Angle Light Scattering with Integrated DLS and Optilab dRI detector.
The instruments currently being installed and qualified across BioPharmaSpecs global laboratories further enhance BioPharmaSpecs already impressive mass spectrometric, chromatographic and spectroscopic service provision.
About BioPharmaSpec
BioPharmaSpec is a CRO specializing in the structural characterization and physicochemical analysis of recombinant biopharmaceuticals, including biosimilars and biobetters, monoclonal antibodies, Antibody Drug Conjugates (ADCs), gene therapy products (i.e. AAV- based therapies), peptides, oligonucleotides and many more product types, with a focus on discovery, early and pre-clinical phases.
Contact:
Lindsay McGowan, Director of Business Development, BioPharmaSpec
Email: l.mcgowan@biopharmaspec.com
For more information, visit https://biopharmaspec.com/
A OESP nao e(sao) responsavel(is) por erros, incorrecoes, atrasos ou quaisquer decisoes tomadas por seus clientes com base nos Conteudos ora disponibilizados, bem como tais Conteudos nao representam a opiniao da OESP e sao de inteira responsabilidade da GlobeNewswire
Leia também
-
Releases Geral Mercado de produtos naturais e orgânicos cresce no Brasil
16 de maio de 2024São Paulo--(DINO - 16 mai, 2024) - Nos últimos anos, o mercado de produtos naturais e orgânicos tem experimentado crescimento significativo no Brasil, impulsionado po
Saiba Mais -
Releases Geral Empresa lança comunidade Keepers.Run para atletas de corrida
4 de dezembro de 2023DINO DIVULGADOR DE NOTÍCIAS (DINO – 04 dez, 2023) – A empresa Keep Running lançou, recentemente, a comunidade Keepers.Run, uma espécie de rede social ou fórum virtual que tem como
Saiba Mais -
Releases Geral Como suprir escassez de talentos nos data centers modernos
25 de outubro de 2023DINO DIVULGADOR DE NOTÍCIAS (DINO – 25 out, 2023) – De acordo com o estudo da Data Centers Dynamics,os principais desafios na hora de construir um centro de dados no país são: falta de
Saiba Mais